MB-PMRB@EC2611A

Norges Bank Increases Stake in Pharmaron by 254,500 Shares, Latest Holding Ratio Reaches 7.07%

BlackRock Reduces Holdings in Kangbok Chemical's H Shares

Three Shareholders of Kanglong Chemical Plan to Reduce 1.57% Equity

Kanglong Chemical's Shareholders Plan to Sell Up to 1.50% Shares

CICC Raises Target Price for Kanghong Chemical to HKD 28

PHARMARON released FY2026 Q1 earnings on April 28 During-Market (BJT), actual revenue HKD 4.057 B (forecast HKD 4.016 B), actual EPS HKD 0.2097 (forecast HKD 0.238)

JPMorgan Reduces Holding in Konica Minolta China to 21.05 Million Shares

PHARMARON to release FY2026 Q1 earnings on April 28 during market hours (BJT), forecast revenue HKD 3.976 B, EPS HKD 0.2349

Morgan Stanley Raises Target Price for Kanglong Chemical to HKD 31.5 and Gives an 'Overweight' Recommendation

CMBI Reiterates Buy Rating on Kangbok Chemical H Shares

Kanglong Chem 完成制剂车间建设并签订战略合作协议

Canlon Chemicals Reports Revenue Growth but Net Profit Decline in 2025

PHARMARON released FY2025 Annual Earnings on March 30 After-Market (BJT), Actual Revenue HKD 15.41 B (Forecast HKD 15.57 B), Actual EPS HKD 1.0266 (Forecast HKD 1.1009)

PHARMARON released FY2025 Q4 earnings on March 30 After-Market (BJT), actual revenue HKD 4.459 B (forecast HKD 4.427 B), actual EPS HKD 0.3243

Kangbashi Establishes New Drug Production Company in Shaoxing

PHARMARON to release FY2025 earnings on March 30 After-Market (BJT), forecast revenue HKD 15.95 B, EPS HKD 1.1242

Norwegian Central Bank Buys Shares in Canbridge Pharma

JPMorgan Reduced Its Stake in ChemPartner to 5.94%

Citi Gives Kanghongcheng a Buy Rating and Positive Catalyst Observation

Norges Bank Sells 1,834,200 Shares of Kanglong Chemical

HINSANG GROUP

RIVERINE CHINA

PASHUN INT RTS

BRAINAURORA-B

SOFTMEDX

GOLDENPOWER

ZHONGKE GROUP

VISION SYNERGY

GEMILANG INTL

GHPC

03759

300759

Goldman Sachs has reaffirmed its Buy rating for Pharmaron Beijing Co., Ltd. Class H, setting a price target of HK$29.70. The stock closed at HK$21.72 last Tuesday. The analyst consensus for Pharmaron is a Strong Buy, with a price target consensus of €3.18.

Tip Ranks

PHARMARON

Pharmaron

Goldman Sachs

GS Hldg R

Goldman Sachs Sticks to Its Buy Rating for Pharmaron Beijing Co., Ltd. Class H (17Q1)

CICC has raised the target price for PHARMARON's Hong Kong shares to HKD28, reflecting a 7.7% increase, supported by strong new orders and solid revenue growth. In Q1 2026, PHARMARON reported a revenue of RMB3.578 billion, up 15.48% YoY, and a net profit of RMB335 million, up 9.75% YoY. CICC maintained its earnings forecasts and an Outperform rating for both A and H shares, citing improved order indicators that enhance earnings visibility.

AASTOCKS News

CICC

CICC Raises PHARMARON  TP to HKD28; Strong New Orders Support Solid Growth

Today, Pharmaron continued its recent weak consolidation trend, with a trading volume of approximately HKD 341 million, and the trading activity was relatively light. However, on the daily MACD level, bullish signals have quietly emerged, with the DIF line beginning to converge with the DEA line and showing signs of a crossover. This typically indicates that the short-selling momentum accumulated during the previous continuous pullback is waning, increasing the likelihood of a phase stabilization. From the recent trend, Pharmaron's stock price has been oscillating in the low range for several trading days, with a clear characteristic of shrinking volume, indicating that selling pressure is gradually easing, but buying power has not yet significantly intervened. On the news front, the CXO industry is currently in a critical observation period for order recovery. Recent market news shows that the number of global innovative drug R&D pipelines continues to grow, and the outsourcing demand from large overseas pharmaceutical companies is rebounding, which is a medium to long-term positive for CRO companies like Pharmaron. Meanwhile, the Federal Reserve's decision to maintain interest rates has limited impact on the global biopharmaceutical financing environment, but Powell's hawkish statements have delayed market expectations for liquidity easing, and in the short term, the risk appetite for growth stocks remains cautious. The Hong Kong pharmaceutical sector has recently seen mixed performance, lacking a unified bullish force. From a technical perspective, Pharmaron's current stock price is operating near the short-term moving averages, and the continuous shrinkage in volume suggests that the market is waiting for a directional choice. If there is a moderate increase in volume in the following trading days and the stock can stabilize above the moving averages, the effectiveness of the bullish signals will significantly increase. It is important to note that the leading company in the CXO sector, WuXi AppTec, fell sharply by 3.7% today, and the sector's linkage effect may weigh on Pharmaron, so attention should be paid to whether the leading company stabilizes

Technical Forecast

WUXI APPTEC

WuXi AppTec

Pre-market trend | Pharmaron (3759.HK) is consolidating with reduced volume on April 29, initial bullish signals are emerging, is it building up for a rebound or a trap for the bulls?

Pharmaron Beijing Co., Ltd. has released its unaudited first-quarter report for 2026, prepared under PRC Accounting Standards and aligned with International Financial Reporting Standards. The announcement, compliant with Hong Kong regulations, details the company's financial performance and governance structure, including its board composition. This transparency aims to bolster investor confidence. The latest analyst rating for Pharmaron's stock (HK:3759) is a Buy, with a price target of HK$28.10. Pharmaron operates in the pharmaceutical sector, providing research and development services.

Pharmaron Beijing Issues Unaudited First-Quarter 2026 Report Under Hong Kong Rules

02359

603259

Citi raised WuXi AppTec's target price to HKD 158.5, with a rating of "Buy." Based on an optimistic outlook for Eli Lilly's tirzepatide and orforglipron projects, Citi increased WuXi AppTec's revenue and earnings per share forecasts by 2%. The TIDES business is expected to achieve an annual growth rate of 40% by 2026. If orforglipron is launched in China in 2027, PHARMARON will benefit. The revised forecast incorporates a more optimistic sales outlook for GLP-1 drugs

AASTOCKS

Eli Lilly

Citigroup raises WuXi AppTec's target price to 158.5 yuan, rating "Buy"

03329

BOCOM International Holdings Company has reaffirmed a Buy rating on Pharmaron Beijing Co., Ltd. Class H, setting a price target of HK$32.50. The overall analyst consensus for Pharmaron Beijing Co., Ltd. Class H is a Strong Buy, with an average price target of €3.32.

BOCOM INTL

BOCOM International Holdings Company Reaffirms Their Buy Rating on Pharmaron Beijing Co., Ltd. Class H (17Q1)

512290

159992

516500

Pharmaron's stock price rose 8.61% today, closing at 20.44 yuan, with a trading volume of 9.5382 million shares. Nomura reported that Pharmaron's performance in the fourth quarter of last year met expectations, with revenue and profit increasing by 16% and 41%, respectively. It is expected that revenue will grow by 12% to 18% in 2026. Nomura raised the target price from 26.63 yuan to 27.33 yuan and maintained a "Buy" rating

Guotai CSI Bio-medicine ETF

Yinhua CSI Innovative Drugs Industry ETF

ChinaAMC SSE STAR Biology and Medicine ETF

ChinaAMC CSI Biotechnology Theme ETF

China Merchants CSI Biotechnology Theme ETF

ChinaAMC SSE Health Care ETF Initiating Fund

E Fund CSI Biotechnology Theme ETF

Minsheng Royal CSI Biotechnology Theme ETF

E Fund CSI 300 Health Care ETF

Pharmaron rose over 8% in half a day, receiving a target price upgrade from Nomura

159316

UBS has maintained a Buy rating on Pharmaron Beijing Co., Ltd. Class H, setting a price target of HK$32.90. The shares closed at HK$18.27 last Monday. The analyst consensus for the company is a Moderate Buy, with a price target consensus of €3.64.

E Fund Hang Seng SCHK Innovative Drug ETF

ChinaAMC Hang Seng Biotechnology Technology ETF(QDII)

Bosera Hang Seng Health Care ETF(QDII)

GF CSI HK Innovative Drugs Industry ETF(QDII)

Huatai-PB Hang Seng Innovative Drugs Industry ETF(QDII)

Penghua CSI HK Connect Health Care Composite ETF

Hwabao WP Hang Seng SCHK Innovative Drug Select ETF

Bosera Hang Seng SCHK Innovative Drug Select ETF

Fullgoal Hang Seng SCHK Innovative Drug & Healthcare ETF

China Universal CNI HK Connect Innovative Drugs Industry ETF

Pharmaron Beijing Co., Ltd. Class H (17Q1) Gets a Buy from UBS

002821

002361

000550

The automotive vehicle sector showed strength, with the bus segment leading the gains. Yutong Bus and SG Automotive Group both hit the daily limit, while Zhongtong Bus Holding Co.,LTD, KLM, JMC, and Ankai saw significant increases. The commercial aerospace concept continued its strong performance, with SHENJIAN GUFEN up for 4 consecutive trading days, followed by SHUNHO STOCK, Shaoyang Hydraulic, Zhongheng Design, Jullyar, and Chaojie Precision.
Innovative drug stocks were repeatedly active, with TJPC up for 3 consecutive trading days, followed by Asymchem, Biosan, Pharmaron, HITECK, and Novus Therapeutics

- On March 31, A-shares experienced fluctuations, with the Shanghai index rising by 0.45%, while the ChiNext index fell by 0.41%.  
- Hong Kong stocks opened strong but narrowed their gains, with the Hang Seng index up 0.15%.  
- The bond market showed mixed results, and commodity futures mostly declined, although metals like silver and gold increased.

Wallstreetcn

Asymchem

SHENJIAN GUFEN

HITECK

SHUNHO STOCK

Ankai

SG AUTOMOTIVE GROUP

TJPC

Zhongtong Bus Holding Co.,LTD

YTCO

Shanghai Composite Index Volatile Up, Innovative Drugs and Auto Stocks Rally Mid-day, Commercial Aerospace Active, Hang Seng Tech Index Surges and Falls Back, Tech Stocks Diverge

MB-PMRB@EC2611A(29323.HK)